The 24th China Hi-Tech Fair Opens on November 15 in Shenzhen, China
15.11.2022 20:13:00 EET | Business Wire | Press release
The 24th China Hi-Tech Fair (CHTF 2022) kicked off in Shenzhen on November 15, 2022. Taking place until November 19, this year’s event has been comprehensively upgraded to the largest ever, integrating new product and technology launches, product and solution exhibitions, trade negotiations, and investment finance, across a diverse variety of hi-tech sectors including biomedicine, new materials, modern agriculture, fine chemicals, aerospace, new energy, high-end equipment manufacturing, energy conservation and environmental protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006208/en/
International Pavilion and IT Exhibition of CHTF 2022 (Photo: Business Wire)
CHTF 2022 will gather a total of 5,000 exhibitors, including domestic multinationals and industry champions such as China General Nuclear Power Corporation, Huawei, ZTE, and Han’s Laser, along with hi-tech “little giants” such as: Kemai, a digital payment system provider; Keanda, a rail transit products manufacturer; and Insighters, a medical technology startup.
Also participating are overseas exhibitors from 38 countries including Brazil, Canada, Finland and Russia, some of which will join via CHTF 2022’s virtual platform. Among them, the Russian Ministry of Education and Technology and the Bavarian State Government of Germany, two of CHTF’s longstanding cooperation partners, have been sending delegations to CHTF for more than 20 consecutive years.
CHTF 2022 will host the inaugural Water Conservation and Innovation Exhibition, which together with a high-tech talent attraction show and an expo for emergency safety will boost the appeal of the event.
Meanwhile, the CHTF Hi-Tech Forum will be held on November 15-17, with a key focus on the digital economy, metaverse, quantum computing, AI, cloud computing, “lighthouse” factories and smart cities, future mobility, and “dual-carbon” goals. The forum will be livestreamed here.
The X-Lake Forum 2022, as the main side-forum of CHTF 2022, was held on November 15. Focused on “openness, integration and future”, this forum discussed development trends and shared cutting-edge hi-tech innovations. John Lee, Chief Executive of the Hong Kong Special Administrative Region; Ho Iat-seng, Chief Executive of the Macao Special Administrative Region; and Ciyong Zou, Director at UNIDO delivered video speeches. Scholars, academicians and renowned industry leaders including Nobel Laureate Roger D. Kornberg delivered keynote speeches at the forum.
More information is available on https://www.chtf.com/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006208/en/
Contact information
For exhibitor and visitor
Ms. XIE Yan, +8675582848652, selenaxie@chtf.com
Ms. WANG Peggie, +8675582848962, wangyq@chtf.com
Ms. CUI Can, +8675582848764, cathy_cui@chtf.com
Ms. YANG Dan, 86 755 8284 8695, yangd@chtf.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom